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Abstract

Neuropeptide Y (NPY), a 36-amino acid peptide, is widely distributed in the central and peripheral nervous
systems and other peripheral tissues. It takes part in regulating various biological processes including food
intake, circadian rhythm, energy metabolism, and neuroendocrine secretion. Increasing evidence indicates
that NPY exerts multiple regulatory effects on stem cells. As a kind of primitive and undifferentiated cells,
stem cells have the therapeutic potential to replace damaged cells, secret paracrine molecules, promote
angiogenesis, and modulate immunity. Stem cell-based therapy has been demonstrated effective and
considered as one of the most promising treatments for specific diseases. However, several limitations still
hamper its application, such as poor survival and low differentiation and integration rates of transplanted stem
cells. The regulatory effects of NPY on stem cell survival, proliferation, and differentiation may be helpful to
overcome these limitations and facilitate the application of stem cell-based therapy. In this review, we
summarized the regulatory effects of NPY on stem cells and discussed their potential applications in disease
therapy.
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Neuropeptide Y (NPY), a 36-amino acid peptide, is widely distributed in the central and peripheral nervous systems and other
peripheral tissues. It takes part in regulating various biological processes including food intake, circadian rhythm, energy
metabolism, and neuroendocrine secretion. Increasing evidence indicates that NPY exerts multiple regulatory eﬀects on stem
cells. As a kind of primitive and undiﬀerentiated cells, stem cells have the therapeutic potential to replace damaged cells, secret
paracrine molecules, promote angiogenesis, and modulate immunity. Stem cell-based therapy has been demonstrated eﬀective
and considered as one of the most promising treatments for speciﬁc diseases. However, several limitations still hamper its
application, such as poor survival and low diﬀerentiation and integration rates of transplanted stem cells. The regulatory eﬀects
of NPY on stem cell survival, proliferation, and diﬀerentiation may be helpful to overcome these limitations and facilitate the
application of stem cell-based therapy. In this review, we summarized the regulatory eﬀects of NPY on stem cells and discussed
their potential applications in disease therapy.

1. Introduction
NPY, a 36-amino acid neuropeptide, was ﬁrst isolated by
Tatemoto et al. from swine brain in 1982 [1]; it belongs to
the pancreatic polypeptide family together with pancreatic
polypeptide (PP) and peptide YY (PYY). NPY, whose structure is characterized by a large number of tyrosine residues
(5 of 36 amino acid residues) and an amidated C-terminal
group, remained highly conserved among species in the
course of evolution [2]. As one of the most abundant neuropeptides, NPY is widely present in the central and peripheral
nervous systems (CNS/PNS) and is a crucial mediator for
other peripheral tissues. In the CNS, it is distributed in
regions such as the cerebral cortex, hypothalamus, brainstem, hippocampus, striatum, and limbic structures [2–4].
In the PNS, it is expressed in sympathetic ganglia and costored and coreleased with noradrenaline during sympathetic
nerve stimulation [5]. Mounting evidence indicates that
NPY expresses in many peripheral tissues such as the retina,
bone, adipose tissue, adrenal medulla, and platelets [6–10].

Consistent with its wide distribution, NPY has been implicated in a variety of biological processes including food
intake, circadian rhythm, energy metabolism, cardiovascular
function, and neuroendocrine secretion [11–15].
Five NPY receptors (Y1, Y2, Y4, Y5, and y6) have been
identiﬁed in mammals, which all belong to the super family
of G protein-coupled receptors. However, the Y4 receptor
has limited aﬃnity for NPY [16]. The y6 receptor is not functional in primates as their y6 gene exists in a truncated version missing the seventh transmembrane domain [17, 18].
NPY receptors are also widely distributed in central and
peripheral tissues of which each receptor exhibits diﬀerent
distributions and mediates their speciﬁc functions [19].
Stem cells are a kind of primitive and undiﬀerentiated
cells which are characterized by perpetual self-renewal and
the potency to diﬀerentiate into specialized cell types. Based
on their origin, stem cells can be categorized into two types:
embryonic stem cells (ESCs) and non-ESCs [20]. The nonESCs are derived from adult and fetal tissues including hematopoietic stem cells, bone marrow mesenchymal stem cells,
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Figure 1: Main eﬀects of NPY on diﬀerent stem cells. NPY exerts multiple regulatory eﬀects on MSC functions, including proliferation
(via Y5R), diﬀerentiation (via Y2R and Y1R), migration, tube formation, and expression of VEGF and CXCR4. NPY could promote the
proliferation and diﬀerentiation of NSPCs through corresponding Y receptors. Meanwhile, NPY could stimulate the proliferation and
diﬀerentiation of ADSCs as well as the survival and mobilization of HSPC. In addition, exogenous NPY supports the long-term
self-renewal and proliferation of undiﬀerentiated ESCs via the Y1 and Y5 receptors. In the ﬁgure, the NPY receptor symbols
symbolized their functional involvement in the regulation of NPY on diﬀerent stem cells. NSPCs—neural stem/precursor cells;
MSCs—mesenchymal stem cells; HSPC—hematopoietic stem/progenitor cells; ADSCs—adipose-derived stem cells; ESCs—embryonic
stem cells; SVZ—subventricular zone; SCZ—subcallosal zone.

adipose-derived stem cells, neural stem cells, and dental pulp
stem cells [21]. Stem cells have the therapeutic potential to
replace damaged cells, secrete paracrine molecules, promote
angiogenesis, modulate immunity, and facilitate tissue repair
[22, 23]. Hence, the eﬃcacy of stem cell-based therapy has
been described in many diseases including myocardial
infarction, stroke, neuritis, liver cirrhosis, pulmonary ﬁbrosis, spinal cord injuries (SCI), Parkinson’s disease, and
Alzheimer’s disease [24–31]. However, some limitations still
hamper the application of stem cell-based therapy, such as
poor survival, oncogenic potential, and low diﬀerentiation
and integration rates, which need to be further researched
to open up new avenues for the therapy.

2. Effects of NPY on Stem Cells
Increasing researches indicate that NPY exerts regulatory
eﬀects on the proliferation, diﬀerentiation, and survival
of stem cells, which is speculated to have potential applications in treatment for many diseases. Here, we reviewed
the eﬀects of NPY on diﬀerent stem cells and the involved
mechanisms (Figure 1).
2.1. NPY and Neural Stem/Precursor Cells (NSPCs)
2.1.1. Hippocampal Precursor Cells. Howell et al. uncovered
that NPY increased the neurosphere formation of early postnatal rat-derived primary hippocampal cultures as well as the
5-bromo-2-deoxyuridine (BrdU) incorporation of nestin+
hippocampal precursor cells, which indicated that NPY

could promote the proliferation of hippocampal precursor
cells. Besides using NPY receptor agonists and antagonists
as well as Y1 receptor knockout (Y1−/−) mice, they further
demonstrated that the proliferative eﬀect of NPY on hippocampal precursor cells was mediated via Y1 receptor [32].
Subsequent study of this research group proved that NPY
displayed proliferative eﬀect on neuronal precursors in
the dentate gyrus. There were increased total cells, neurons
(class III β-tubulin expressing cells), and cell proliferation
in postnatal rat-derived dentate gyrus cells cultured in
medium with l μM NPY than that cultured in control
medium, of which the neuroproliferative eﬀect of NPY was
mediated by Y1 receptor and involved ERK1/2 activation.
Meanwhile, in Y1−/− mice, the proliferation rate and immature doublecortin-positive neurons in the dentate gyrus were
signiﬁcantly reduced [33]. In vivo, exogenous NPY also
exhibits proliferative eﬀect on neural progenitors in the
dentate gyrus. Decressac et al. demonstrated that intracerebroventricular (ICV) injection of NPY to C57BL/6
mice promoted the proliferation of neural progenitors
and neuroblasts in the dentate gyrus, and ICV injection
of Y1 receptor agonist could mimic this proliferative eﬀect.
However, when coinjected with Y1 receptor antagonist or
injected to Y1−/− mice, NPY could not induce the proliferation in the dentate gyrus, indicating that the proliferative
eﬀect of NPY is mediated via Y1 receptor [34]. In short, the
mechanism involved in NPY-stimulated hippocampal precursor cell proliferation may be mediated by Y1 receptor/
intracellular nitric oxide (NO)/cyclic guanosine monophosphate (cGMP)/cGMP-dependent protein kinase (PKG)/
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extracellular signal-regulated kinase (ERK) 1/2 signaling
pathway [35].
In the aspect of promoting hippocampal precursor proliferation, NPY is able to display synergistic action with other
proliferative factors. Rodrigo and colleagues found that the
combination of NPY and ﬁbroblast growth factor 2 (FGF2)
more potently stimulated proliferation of nestin+ hippocampal neural stem progenitor cells (NSPCs) than either factor
alone. On the one hand, NPY increased FGF receptor1
(FGFR1) mRNA and protein expression in NSPCs. On the
other hand, NPY augmented the proliferative eﬀect of
FGF2 via Y1 receptor through shortening the cell cycle time
of NSPCs [36].
The proliferative eﬀect of NPY on hippocampal precursor cells presents not only in normal condition but also in
pathological conditions. NPY−/− mice displayed lower level
of BrdU incorporation in dentate gyrus subgranular zone
(SGZ) under the conditions of basal and kainic acid- (KA-)
induced seizure, which suggested a role for NPY in seizureinduced proliferation of hippocampal precursor cells [37].
Baptista et al. administered the psychostimulant drug methamphetamine (METH) to dentate gyrus-derived neurosphere cultures and found METH decreased neuronal
diﬀerentiation of the neurosphere cultures at low concentration and induced cell death at high concentration. Besides,
NPY prevented METH-reduced neuronal diﬀerentiation
and METH-induced cell death, meanwhile NPY promoted
the proliferation of dentate gyrus-derived neurosphere
cultures [38].
2.1.2. Subventricular Zone (SVZ) Neural Precursor Cells.
Agasse et al. gave mice-derived SVZ neurosphere NPY treatment and found that NPY promoted the proliferation and
neuronal diﬀerentiation of SVZ cells and, particularly, the
proneurogenic eﬀect of NPY was mediated via Y1 receptor
and involved activation of ERK1/2 and stress-activated protein kinase (SAPK)/c-Jun-NH2-terminal kinase (JNK) signaling [39]. The regulatory eﬀects of NPY on SVZ neural
precursors were further demonstrated in vivo. Compared
with wild-type (WT) mice, there were signiﬁcantly reduced
proliferating precursor cells and neuroblasts in SVZ of
Y1−/− and Y2−/− mice [40]. Researchers administrated ICV
injection of saline, NPY, Y1 receptor agonist, or a mixed solution of Y1 receptor antagonist and NPY, respectively, to adult
mice and investigated the proliferation of SVZ cells at 48 h
after injection. The results showed that NPY and Y1 receptor
agonist stimulated the proliferation of SVZ neural precursors
signiﬁcantly. In contrast, the proliferative eﬀect of NPY was
inhibited by Y1 receptor antagonist, which suggested Y1
receptor mediated this proliferative eﬀect of NPY. Meanwhile, the researchers substantiated that NPY augmented
the migration of newly generated neuroblasts which were
formed in the SVZ toward the striatum and olfactory bulb
through rostral migratory stream [41]. Additionally, Thiriet
et al. discovered that SVZ cells produced endogenous NPY
which indicated that NPY may act as a paracrine/autocrine
factor in SVZ. They also demonstrated that NPY promoted
the proliferation and neuronal diﬀerentiation of SVZ cells,
which were isolated from newborn rats, via Y1 receptor-
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mediated ERK1/2 MAP kinase pathway [42]. Accordingly,
these results indicated that NPY could promote the proliferation and neuronal diﬀerentiation of SVZ neural precursor
cells via Y1 receptor; although Y2−/− mice also had reduced
proliferating precursor cells and neuroblasts in SVZ as
Y1−/− mice, the exact eﬀects of Y2 receptor in proliferation
and diﬀerentiation of SVZ neural precursor cells were still
unclear which may be mediated by Y2 receptor itself or by
regulating Y1 receptor expression or by other mechanisms.
Further studies are needed to better understand this process.
2.1.3. Subcallosal Zone (SCZ) Precursor Cells. Unlike the
hippocampus and subventricular zone around the lateral
ventricle which regenerate neurons in mammalian adulthood, SCZ predominately generates oligodendrocytes. Interestingly, seizure could promote the SCZ activity thereby
producing more glial progenitors which migrate to the
impaired hippocampus [43]. It has been reported that
NPY−/− mice had signiﬁcantly reduced proliferative (BrdU
positive) cells in the left subcallosal zone under basal condition; meanwhile, seizure-induced proliferation in the SCZ
of NPY−/− mice also decreased compared with WT control,
which suggested that NPY played a role in the proliferation
of SCZ precursor cells [44]. Thus, it points out a signiﬁcative
possibility that NPY promotes hippocampal neurogenesis
through inducing SCZ oligodendrogliogenesis.
2.1.4. Olfactory Neuronal Precursor Cells. The neuroproliferative eﬀect of NPY was primarily identiﬁed in olfactory epithelium. Hansel and colleagues uncovered that NPY−/− mice had
decreased proliferation of olfactory neuronal precursor cells
in the olfactory epithelium. They performed experiments
with primary olfactory cultures to demonstrate that NPY
facilitated the proliferation of neuronal precursor cells via
Y1 receptor and involved protein kinase C (PKC)/ERK1/2
signaling [45]. The role of NPY and Y1 receptor in proliferation of olfactory precursor cells was further conﬁrmed
in subsequent studies. Doyle et al. reported that primary
adult olfactory precursor cells derived from NPY−/−, NPY/
PYY−/−, and Y1−/− mice formed reduced olfactory neurospheres compared with WT mice and only WT controlderived glandular cells could form secondary neurospheres,
suggesting an important role of NPY signaling in proliferation of olfactory precursor cells. Furthermore, they also discovered that Y1−/− mice exhibited impaired olfaction
compared with WT mice which may result from reduced formation of olfactory neurons [46]. Pathological examination
of the olfactory neuroepithelium derived from NPY−/− and
WT mice revealed that there were signiﬁcantly fewer number
of olfactory receptor neurons in olfactory neuroepithelium of
NPY−/− mice [47].
Furthermore, NPY is associated with neuroregeneration
of olfactory epithelium under pathological conditions. In
the olfactory epithelium, adenosine triphosphate (ATP) is
released upon injury and stimulate proliferation and diﬀerentiation of olfactory neuronal precursors via P2 purinergic
receptor [48]. It has been reported that intranasal instillation
of ATP enhances the expression of NPY in olfactory epithelium sustentacular and microvillous cells via P2 purinergic
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2.1.5. Retinal Neural Progenitor Cells. It has been reported
that NPY could promote the proliferation of retinal neural progenitor cells and retinal neural cells. The application of exogenous NPY to primary rat retinal cell
cultures for 48 h promoted retinal neural cell proliferation
signiﬁcantly, and the proliferation of nestin+ retinal neural
progenitor cells in this culture was increased at the same
time. These proliferative eﬀects of NPY are mediated via Y1,
Y2, and Y5 receptors through activation of NO-cGMP and
ERK1/2 pathway [53]. The general opinion is that the
mature mammalian retina was short of regenerative capacity
[54] but the proliferative eﬀects of NPY on retinal neural
progenitor cells and retinal neural cells provide experimental evidence and novel strategy for regeneration of
the injured retina.

reported that BMCs from Y1−/− mice formed more mineralized nodules under osteogenic conditions and more
adipocytes under adipogenic conditions, compared with
wild-type control. Meanwhile, the MSCs and mesenchymal
osteoprogenitor cells isolated from the bone of Y1−/− mice
have enhanced ability to diﬀerentiate into osteoblasts and
adipocytes, which indicated that NPY could suppress the
diﬀerentiation of mesenchymal progenitor cells via Y1
receptor [58]. Besides, previous research showed that exogenous NPY promoted osteoblast diﬀerentiation of primary
mouse BMCs through Y2 receptor [59]. However, Liu and
colleagues discovered that NPY enhanced osteoblastic differentiation of rat BMSCs in a concentration-dependent
manner via Y1 receptor and Wnt signaling pathway [60].
Recent study indicated that NPY promoted the osteogenic
diﬀerentiation of health volunteer-derived BMSCs and
increased the expression of Y1 receptor in human BMSCs
[61]. In view of these serial researches, we concluded that in
mice, NPY could promote the osteoblastic diﬀerentiation of
MSCs via Y2 receptor and inhibit MSCs diﬀerentiating into
osteoblasts via Y1 receptor. Moreover, Y2 receptor exhibited
dual feedback inhibition on MSC osteoblastic diﬀerentiation
through feedback inhibition on NPY release, thereby regulating the expression level of Y1 receptor. However, in rats
and human, it has been reported that NPY promoted the
osteoblastic diﬀerentiation of MSCs through Y1 receptor.
These conﬂicting results in diﬀerent species need to be
further investigated.

2.2. NPY and Mesenchymal Stem Cells (MSCs). Wang and
colleagues found that pretreating rat bone marrow mesenchymal stem cells (BMSCs) with NPY for 72 h upregulated
the expression of vascular endothelial growth factor (VEGF)
and genes required for mitosis, including aurora B kinase,
FGF-2, cyclin A2, eukaryotic initiation factor 4E, and stromal
cell-derived factor-1α, when under hypoxia condition.
Meanwhile, NPY pretreatment promoted the migration of
BMSCs through upregulating CXCR4 expression and
induced endothelium diﬀerentiation as well as tube formation of BMSCs [55]. It has been reported that NPY enhanced
the proliferation of rat bone marrow stromal cells (BMCs)
which was mediated via Y5 receptor. The proliferative
response to NPY of BMCs isolated from old rats is weaker
than those isolated from neonatal and young rats, because
of the decreased expression of Y5 receptors in old BMCs.
Furthermore, Y5 receptor gene transfection restored the
impaired growth potential of old BMCs [56].
Recent studies have demonstrated that NPY system
displays regulatory eﬀects on osteoblastic and adipogenic
diﬀerentiation of MSCs. Compared with wild-type control,
BMCs derived from Y2−/− mice cultured under osteogenic
and adipogenic conditions exhibited increased mineralization and adipocyte formation, respectively [57]. The Y1
receptor mRNA expression of BMCs cultured from Y2−/−
mice was downregulated, which maybe a result from the
lack of Y2 receptor signaling relieved the feedback inhibition
on NPY release, and elevated NPY caused overstimulation of
Y1 receptors and followed by desensitization and downregulation of Y1 receptor [57]. In a follow-up study, Lee et al.

2.3. NPY and Hematopoietic Stem/Progenitor Cells (HSPC). It
was reported that NPY was of great importance in the survival and mobilization of HSPC. Park et al. uncovered that
there were reduced hematopoietic stem cells (HSCs) in the
bone marrow of NPY−/− mice and these mice had fewer
SNS ﬁbers and CD31+ ECs in bone marrow. Through investigating the cause and eﬀect relationships, they concluded
that NPY deﬁciency caused p53-dependent apoptosis of
SNS ﬁbers and/or CD31+ ECs in the bone marrow, resulting
in impairment of HSC survival. Further pharmacological
experiments of NPY increase and Y1 receptor intervention
illustrated that NPY/Y1 receptor regulation aﬀected HSC
survival by reducing apoptosis of SNS ﬁbers and ECs in
marrow microenvironment [62]. As a recent study showed,
compared with WT control, the HSPC mobilization in
NPY−/− mice was impaired which resulted from the
decreased matrix metalloproteinase-9 (MMP-9) activity in
bone marrow-induced upregulation of HSPC maintenance
factors. Besides, exogenous NPY or elevation of endogenous
NPY by stress stimulated MMP-9 activity of osteoblast via
Y1 receptor thereby suppressing HSPC maintenance factors
and inducing HSPC mobilization in mice [63]. Hence, these
stimulatory eﬀects of NPY on survival and mobilization of
HSPC were mediated through regulating hematopoietic
stem cell niche. The HSC niche is critical to support HSC
function and to maintain a proper balance between selfrenewal and multilineage diﬀerentiation. Various types of
cells have been identiﬁed as HSC niche components which
include osteoblasts, stromal cells, vascular endothelial cells,
macrophages, adipocytes, and megakaryocytes [64, 65].

receptors and NPY stimulates the proliferation of neuronal
progenitor cells through Y1 receptor-mediated ERK1/2 activation [49, 50]. A subtype of microvillous cells which express
inositol triphosphate receptor subtype 3(IP3R3) plays a
critical role in neuroregeneration and recovery after olfactory epithelium injury as they secrete suﬃcient NPY [51].
A recent study showed that the number of IP3R3+NPY+
microvillous cells and expression of NPY in mouse olfactory epithelium existed an age-dependent decline. In addition, the number and proliferation of olfactory stem cells
also decreased with age, suggesting a role of NPY in agerelated olfactory dysfunction [52].
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Not only osteoblasts that was mentioned above but also
vascular endothelial cells, macrophages, and adipocytes
have been identiﬁed to be regulated by NPY [62, 66, 67],
which indicated the potential that NPY could regulate the
function of HSPC via these HSC niche component cells.
Additionally, previous studies showed that NPY is expressed
by bone marrow hematopoietic cells [62, 68] which indicated
that HSPC may exert feedback regulation on HSC niche via
releasing NPY.
2.4. NPY and Adipose-Derived Stem Cells (ADSCs). Wu et al.
researched the eﬀects of NPY at diﬀerent concentrations
on proliferation and diﬀerentiation of cultured human
adipose-derived stem cells (hADSCs). The results revealed
that NPY stimulated the proliferation of hADSCs at low
concentrations (10−14–10−11 mol/L), however, at high concentrations (10−10–10−6 mol/L), NPY inhibited the proliferation and promoted adipogenic diﬀerentiation of hADSCs
[69]. Yang et al. uncovered that rat primary preadipocytes
and 3T3-L1 cells (a murine preadipocyte cell line) expressed
abundant Y1 receptors, and at the same time, NPY promoted
the proliferation of rat primary preadipocytes and 3T3-L1
cells in a concentration-dependent manner via Y1 receptor
and related to the ERK1/2 pathway [70]. Meanwhile, it
was reported that visceral adipose tissue [70] and abdominal
subcutaneous adipose tissue [71] synthesized NPY, which
indicated that adipose tissue may release NPY in an autocrine
manner thereby promoting the proliferation and adipogenic
diﬀerentiation of its resident ADSCs and adipocyte precursor
cells, and consequently result in the further accumulation of
the adipose tissue.
2.5. NPY and Embryonic Stem Cells (ESCs). Son and colleagues uncovered that undiﬀerentiated human ESCs
expressed NPY, Y1, and Y5 receptors and exogenous NPY
supported the long-term self-renewal and proliferation of
undiﬀerentiated human ESCs via the Y1 and Y5 receptors
involving the activation of AKT, ERK1/2, and cAMPresponse element-binding (CREB) signaling [72]. Based on
the regulatory eﬀect of NPY on human ESC self-renewal, this
group designed a novel chemically deﬁned medium with
NPY supplement which could support the long-term culture
of human ESCs without feeder cells and serum [72]. The
traditional ESC culture needs the support of inactivated
mouse embryo ﬁbroblast and fetal calf serum. However, the
indeterminacy of feeder cell secretion and potential pathogen
contamination of serum hinder the research and application
of ESCs. The development of a xeno-free and serum-free
medium that supports the long-term culture derivation and
large-scale propagation is still one of the major challenges
for the clinical application of ESCs. Therefore, the chemically
deﬁned medium with NPY supplement may become a novel
strategy for ESC translational research. Additionally, NPY
takes part in stress-induced adipogenesis of ESCs. As a study
showed, stress hormone epinephrine (EPI) facilitated the
expression of NPY, Y1, and Y2 receptors in murine ESCs,
of which EPI enhanced the adipogenic diﬀerentiation of
murine ESCs via the NPY system [73].
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3. Potential Application of NPY’s Regulatory
Effects on Stem Cells
3.1. Neurodegenerative Diseases. Neurodegenerative diseases
are a group of disorders originating from the degeneration
of central neurons that gradually leads to cognitive and/or
motor dysfunctions [74]. These disorders include Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s
disease (HD), multiple sclerosis (MS), and Machado-Joseph
disease (MJD). With an increase in lifespan, the prevalence
of neurodegenerative diseases is increasing signiﬁcantly
[75]. To date, there are no eﬀective treatments for neurodegenerative diseases and the available clinical therapies mainly
help in keeping patients from getting worse for a limited
period of time [76, 77].
In recent years, the eﬀects of NPY on neurodegenerative
diseases and the involved mechanisms have been revealed
gradually. Just as reported previously, NPY inhibited the
phagocytosis, inﬂammatory factor release, and motility of
activated microglial cells, thereby attenuating microgliamediated inﬂammation in injury area of the CNS [78–80].
Aveleira et al. demonstrated that NPY stimulated autophagy of neural cells in in vitro and in vivo experiments,
indicating that NPY could promote the clearance of misfolded and abnormal proteins that caused neurodegenerative diseases through autophagy [81]. Excitotoxicity and
alteration in calcium homeostasis are related to neurodegenerative diseases. Some studies suggested that NPY
reduced glutamate-mediated excitotoxicity and regulated
calcium homeostasis [82–85]. Besides, NPY displays some
ameliorative eﬀects on clinical manifestations of neurodegenerative diseases. Researchers have investigated the antidepressive eﬀects of NPY in rodent forced swim test, and
the results revealed that NPY exerted antidepressant-like
properties via Y1 receptor [86–88]. As an orexigenic agent,
NPY may ameliorate the weight loss in neurodegenerative
diseases [89].
The main physiopathological feature of neurodegenerative diseases is progressive degeneration of neurons; hence,
neuronal replacement is considered as a promising therapeutic strategy for neurodegenerative diseases [90]. Recently,
an increasing number of studies have demonstrated the
regulatory eﬀects of NPY on neuronal precursor cells. NPY
facilitates the proliferation of hippocampal precursor cells
[32, 33] via Y1-receptor-mediated intracellular NO/cGMP/
PKG/ERK1/2 pathway [35]. NPY also promoted the proliferation and neuronal diﬀerentiation of SVZ neural precursors
[39, 42], as well as the migration of newly formed neuroblast
toward striatum and olfactory bulb [41]. The hippocampus
and SVZ are the most active areas of neurogenesis in adult
brain, and the stimulative eﬀects of NPY on neural precursor
proliferation and diﬀerentiation in these regions are likely
to ameliorate neuron loss in neurodegenerative diseases.
Decressac et al. administrated a single ICV injection of
NPY to R6/2 mice (a transgenic model of Huntington’s
disease) and found that NPY improved motor function
and extended survival time of the R6/2 mice through
reduced body weight loss, meanwhile, NPY promoted cell
proliferation and neuroblasts generation in the SVZ of

6
R6/2 mice [91]. In a hippocampal neurodegeneration rat
model induced by trimethyltin (TMT), ICV injection of
NPY decreased TMT-induced hippocampal damage and
stimulated hippocampal neurogenesis through the upregulation of BDNF, Bcl2l1, Bcl-2, Sox-2, Noggin, NeuroD1,
and doublecortin genes [92], and the increased newly born
neurons later integrated into the local hippocampal circuits [93]. Researchers gave APP-transgenic (tg) mouse
(a mouse model of Alzheimer’s disease) CNS-targeted
delivery of NPY, and they discovered that NPY treatment
ameliorated behavioral deﬁcits as well as neurodegenerative pathology of APP-tg mouse and promoted the proliferation of neural precursor cells in subgranular zone of the
APP-tg mouse [94].
3.2. Retinal Degenerative Diseases. Retinal degenerative
diseases, such as age-related macular degeneration, retinopathies, and glaucoma, are a group of ocular diseases characterized by chronic neuronal loss. Currently, there is no
cure for retinal degenerative diseases, the main causes of
vision loss and blindness. The therapeutic potential of
NPY in retinal degenerative diseases has been appreciated
due to its neuroprotection and proliferative eﬀect on retinal
neural progenitor cells.
It has been shown that exogenous NPY inhibited
3,4-methylenedioxymethamphetamine- (MDMA-) induced
necrosis and apoptosis in rat retinal neural cell cultures
[95]. Meanwhile, NPY has protective eﬀects against glutamate and N-methyl-D-aspartic acid- (NMDA-) induced
rat retinal cell death [83, 96]. NPY could inhibit intracellular calcium concentration ([Ca2+]i) changes in cultured
rat retinal neurons through Y1,Y4, and Y5 receptors
[97], which may be one of the mechanisms for the neuroprotective eﬀect of NPY. Furthermore, NPY could inhibit
osmotic swelling of Müller cells via Y1 receptor [98, 99],
and this glial volume regulatory eﬀect of NPY may be related
to its retinal neuroprotection.
Stem cell-based therapy is a novel and promising treatment strategy for retinal degenerative diseases [100]. As
mentioned above, NPY promotes the proliferation of retinal
neural progenitor cells in primary rat retinal cell cultures
[53]. Müller glial cells were identiﬁed as a candidate for
endogenous retinal stem cells which could diﬀerentiate into
certain retinal cell types [101–103]. NPY exerts biphasic
modulatory eﬀect on proliferation of Müller glial cells. It
reduced the proliferation of Müller cells at low concentration,
while at higher concentration, it promoted proliferation
[104]. Thus, the proliferative eﬀects of NPY on retinal
stem/progenitor cells indicate that NPY is a putative target
for retina regeneration.
3.3. Myocardial Infarction. Stem cell therapy is a promising
approach for myocardial infarction (MI) via replenishing
cell loss and supplying cytokines that induce angiogenesis
or activate resident cardiac stem cell migration and commitment to cardiomyocytes [105]. Some major challenges
still plague the stem cell therapy for MI, such as low cell
survival rate and poor engraftment of the transplanted
cells; therefore, new strategies are desired for better
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therapeutic eﬀects in stem cell transplantation [106].
The multiple eﬀects of NPY on stem cells, cardiomyocytes, and angiogenesis may be useful in stem cell-based
therapy for MI.
It has been shown that NPY pretreatment upregulated
the expression of VEGF and mitosis-related genes of rat
BMSCs and promoted the migration, endothelium diﬀerentiation, and tube formation of BMSCs [55]. Researchers
transplanted NPY-pretreated or NPY-untreated BMSCs
into the ischemic ventricular wall of myocardial infarcted
rats. Four weeks later, they uncovered that NPY pretreatment
induced BMSCs to diﬀerentiate into cardiomyocytes and
endothelium cells in the infarcted myocardium and myocardial infarcted rats which received NPY-pretreated BMSCs
exhibited improved cardiac function and reduced ventricular
remodeling and ﬁbrosis than those which received untreated
BMSCs [55].
In a swine model of chronic myocardial ischemia,
NPY treatment improved left ventricular function and
enhanced angiogenesis and arteriogenesis via stimulating
proangiogenic receptor, growth factor expression, and
decreasing antiangiogenic protein expression [107]. In
follow-up studies, researchers applying a swine model of
hypercholesterolemia and chronic myocardial ischemia
demonstrated that local inﬁltration of NPY in ischemic
myocardial improved collateral vessel formation, blood
ﬂow, and myocardial function [108], as well as decreased
cardiomyocytes apoptosis and myocardium ﬁbrosis in the
ischemic region [109]. Furthermore, in vitro experiments
revealed that NPY directly induced neonatal and adult
rat cardiomyocytes cell cycle reentry and promoted their
mitosis and cytokinesis [55]. Thus, given the regulatory
eﬀects of NPY on stem cell and the multifaceted beneﬁcial
eﬀects on ischemic myocardium, it can be speculated that
a combined treatment of stem cells with NPY may be a
novel strategy for ischemic heart disease including myocardial infarction.
3.4. Osteoporosis. In recent years, the regulatory eﬀects of
NPY on osteogenesis and the involved mechanisms have
been revealed, which suggested that NPY could be a novel
therapeutic target for osteoporosis. Lee and colleagues
reported that NPY system inhibited osteoblastic diﬀerentiation of mesenchymal progenitor cells and mineralization of
mature osteoblasts via the Y1 receptor [58]. Researchers gave
C57/BL mice oral administration of BIBO3304 (a selective Y1
receptor antagonist) for 8 weeks and found that this Y1
receptor antagonist increased bone mass of mice in a dosedependent manner and without adverse extraskeletal side
eﬀects [110]. Besides, Liu et al. performing experiments with
rat primary BMSCs discovered that NPY stimulated osteoblastic diﬀerentiation of BMSCs via activating Wnt signaling
pathway [60]. In addition, the promotion of NPY on human
BMSC osteogenic diﬀerentiation has been demonstrated in
in vitro experiments [61]. Although it has not been
reported, we can speculate that the regulation of NPY on
the osteogenic diﬀerentiation of BMSCs may play a role
in the treatment of osteoporosis. As recent studies showed,
NPY also aﬀected bone homeostasis through regulating
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Figure 2: Potential application of NPY’s regulatory eﬀects on stem cells. Animal experiments have demonstrated the potential to utilize
the regulatory eﬀects of NPY on stem cells for disease treatment (solid violet arrow). Meanwhile, some potential applications could be
hypothesized (dotted violet arrow). Besides, given the beneﬁcial eﬀects of NPY itself on these diseases (solid green arrow), combined use
of stem cells with NPY may be a novel treatment strategy. NPY—neuropeptide Y; NSPC—neural stem/precursor cell; MSC—mesenchymal
stem cell; HSPC—hematopoietic stem/progenitor cells; ADSC—adipose-derived stem cell; CNS—central nervous system.

hematopoietic stem/progenitor cell (HSPC) mobilization.
Park and colleagues demonstrated that NPY induced
HSPC mobilization by decreasing HSPC maintenance factor expression via activating matrix metalloproteinase-9 in
osteoblasts [63]. And in a mouse model of ovariectomyinduced osteoporosis, NPY treatment ameliorated bone
loss by decreasing the number of osteoclasts via increased
HSPC mobilization [63]. In subsequent study, this group
constructed two NPY-based peptides which were recombined from the cleavage of NPY. These new NPY peptides
reduced bone loss in ovariectomized mice more eﬀectively
than the full-length NPY, suggesting their potential application in osteoporosis [111].
Furthermore, NPY system still regulates bone homeostasis at the CNS level. In wild-type mice, overexpression of
hypothalamus NPY resulted in decrease of osteoblast activity
[112]. When Y2 receptor was hypothalamus speciﬁc deleted
in mice, there was a marked increase in the cancellous and
cortical bone volume [113]. The y6R in suprachiasmatic
nucleus is required for maintenance of bone mass in mice
as it stimulates bone formation and suppresses bone resorption [114]. In general, NPY system exerts multiple regulatory

eﬀects on bone homeostasis at CNS and peripheral levels,
suggesting that regulating NPY activity may be a novel strategy for osteoporosis treatment.
3.5. Obesity. NPY has been demonstrated to have critical
eﬀects on the development of obesity through promoting
appetite and decreasing energy expenditure [115–117].
Additionally, NPY could directly regulate adipogenesis in
peripheral tissues. NPY stimulates the proliferation of
hADSCs at low concentration and promotes its adipogenic
diﬀerentiation at high concentration [69]. The ability of
mouse bone marrow stromal cells to diﬀerentiate into adipocytes was enhanced in the absence of Y1 receptor [58]. NPY
also facilitates the proliferation of rat primary preadipocytes
and 3T3-L1 preadipocytes in a concentration-dependent
manner via Y1 receptor-mediated activation of ERK1/2 signaling pathway [70] and facilitates adipogenic diﬀerentiation
of 3T3-L1 preadipocytes via Y2 receptor [71]. In vivo,
administration of a NPY pellet in subcutaneous abdominal
fat of mice increased the weight and volume of adipose tissue,
illustrating the ability of NPY to locally stimulate adipogenesis [71, 118]. Therefore, therapeutic strategies which target

8

Stem Cells International

the NPY system in peripheral tissue may facilitate intervention for obesity.

4. Conclusions
In summary, NPY exerts multiple regulatory eﬀects on
stem cell activities including proliferation, diﬀerentiation,
self-renewal, factor secretion, migration, and mobilization.
NPY could be applied as an adjunct for stem cell grafting
and facilitate tissue regeneration as appropriate. Existing
data provide evidence that there are potential applications
of NPY’s regulatory eﬀects on stem cells in treatment of
some important diseases (Figure 2). However, it is still
in its infancy. The knowledge about eﬀects of NPY on
ESCs, HSPC, and induced pluripotent stem cells (iPSCs)
are still limited. Further studies are needed to unravel
the eﬀects and mechanisms of NPY on diﬀerent kinds of
stem cells, as well as the eﬃciency and safety in the stem
cell-based therapy.
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